Background Liraglutide is a human glucagon-like peptide-1 analogue (GLP-1) indicated in the treatment of adults with type-2 diabetes mellitus to achieve glycaemic control, combined with oral antidiabetic agents, increases insulin secretion and decreases glucagon secretion, in a glucose-dependent manner.
Purpose To analyse the adequacy and effectiveness of liraglutide in patients with type-2 diabetes mellitus.
Material and methods Retrospective 2 year observational study (September 2014 to September 2016) of all patients with type-2 diabetes mellitus treated with liraglutide for at least 6 months. Data were obtained from the application of laboratory tests, electronic medical records (DIRAYA) and the application of endorsements. The variables collected were: sex, age, time of initiation of treatment with liraglutide and value of glycosylated haemoglobin (HbA1c) before and after 6 months of treatment. Adequate use of liraglutide was considered when baseline HbA1c was greater than or equal to 7.5% and treatment was effective if reduction of HbA1c at 6 months was greater than or equal to 1%.
Results The total number of patients with type-2 diabetes mellitus treated with liraglutide during the study period was 32. Six patients were excluded due to lack of data. Of the remaining 26 patients, 14 (54%) were females with a median age at the start of treatment of 51 years (37–68). According to the HbA1c values, 73% of the patients met the criteria of adequacy of liraglutide use. Median HbA1c at baseline: 8.6% (5.4–13.6) and median HbA1c at 6 months of treatment: 7.4% (5.2–10.6). For 11 patients (42%), treatment with liraglutide was considered effective. In all but two, there was a decrease in HbA1c. The mean decrease in Hb1Ac in successful patients was 1.03%.
Conclusion Several studies have shown that the addition of liraglutide to oral antidiabetic drugs is associated with better glycaemic control in patients with type-2 diabetes mellitus. In our study, despite adequate use in most patients, the decrease in HbA1c was not sufficient to be considered effective in more than half of the patients.
Reference and/or Acknowledgements 1. Levin PA, Nguyen H, Wittbrodt ET. Glucagon-like-peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes2017Apr 4;10:123–139.
No conflict of interest
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.